{"id":30335,"date":"2026-06-17T17:37:14","date_gmt":"2026-06-17T12:07:14","guid":{"rendered":"https:\/\/www.medicalbillersandcoders.com\/blog\/?post_type=wpseo_locations&p=30335"},"modified":"2026-06-17T18:10:53","modified_gmt":"2026-06-17T12:40:53","slug":"neurology-billing-partner-in-texas","status":"publish","type":"wpseo_locations","link":"https:\/\/www.medicalbillersandcoders.com\/blog\/locations\/neurology-billing-partner-in-texas\/","title":{"rendered":"Which Neurology Billing Partner in Texas Protects Your Most Valuable Revenue Streams?"},"content":{"rendered":"

The neurology billing partner in Texas<\/strong> that protects your most valuable revenue streams is one built to deliver Novitas Solutions LCD-compliant neurodiagnostic coding, EEG and EMG documentation that survives Medicare Advantage algorithmic review, high-complexity E\/M audit defense, and infusion therapy prior authorization management \u2014 the four revenue categories where generic medical billing services in Texas<\/a><\/strong> consistently fail.<\/p>\n

According to AAN benchmarking data, top-performing neurology practices collect 94%\u201397% of collectible revenue; the specialty average sits 9%\u201313% below that threshold, representing $400,000\u2013$900,000 in preventable revenue leakage<\/strong> per physician group per 12 months.<\/p>\n

\n

Why Texas Makes Neurology Billing Harder Than Most States<\/h3>\n

Texas presents a uniquely complex neurology billing<\/a><\/strong> environment driven by three compounding payer pressures that generalist RCM vendors are structurally unequipped to manage.<\/p>\n

Medicare Advantage penetration in Texas exceeds the national average across Houston, Dallas-Fort Worth, San Antonio, and Austin \u2014 meaning a disproportionate share of Texas neurology claims flow through MA plans that deploy NLP-based algorithmic review to auto-downcode diagnostic interpretations at 2.4 times the traditional Medicare denial rate.<\/p>\n

Texas Medicaid managed care administered through STAR and STAR+PLUS imposes prior authorization requirements on neurodiagnostic procedures, infusion therapies, and specialist referrals that create AR Aging cycles of 50\u201380 days for groups without dedicated authorization management workflows. And Texas neurology practices fall under Novitas Solutions MAC<\/strong> jurisdiction with specific LCD enforcement on neurological diagnostic procedures that most generalist vendors address with the same reactive appeals process they apply to every other specialty.<\/p>\n

The result is compounding payer variance across high-volume payer categories that generic billing vendors absorb as routine write-offs \u2014 and that MBC’s Revenue Integrity Framework is specifically engineered to eliminate.<\/p>\n

\n

The Triple Threat to Texas Neurology Group Margins:<\/h3>\n

1. Novitas LCD Non-Compliance on Neurodiagnostic Procedures<\/strong><\/p>\n

EEG (CPT 95816, 95819, 95827), EMG (CPT 95860\u201395864), and nerve conduction studies (CPT 95907\u201395913) are among Novitas’s most actively enforced LCD categories. Practices submitting without pre-authorization documentation review average denial rates of 11%\u201315% on these procedures \u2014 translating to $110,000\u2013$180,000 in annual revenue leakage for groups performing 200+ neurodiagnostic studies per month.<\/p>\n

2. Infusion Therapy Undercoding and Prior Authorization Failures<\/strong><\/p>\n

MS biologic infusion billing \u2014 natalizumab (J2323), ocrelizumab (J2350), ofatumumab (J3061) \u2014 requires HCPCS-level precision on dosing units, site-of-service modifiers, and prior authorization compliance that generic RCM vendors cannot reliably produce. Dosing unit miscounts and missing modifiers alone average $85,000\u2013$140,000 in per-12-month revenue loss for practices running active infusion suites.<\/p>\n

3. High-Complexity E\/M Downcoding Under MDM Documentation Rules<\/strong><\/p>\n

The 2021 AMA E\/M MDM revision eliminated time-based coding shortcuts that many Texas neurology practices had relied upon for 99215 capture. Without proactive documentation protocol updates, practices are systematically downcoded from 99215 to 99214 \u2014 a $48\u2013$62 loss per visit that compounds to $290,000\u2013$470,000 per 12 months for a high-volume neurology group. Per CMS E\/M guidelines, the CPT E\/M guidelines for MDM apply to all office\/outpatient visits, making proactive documentation audits non-negotiable for high-volume neurology practices.<\/p>\n

\n

Neurology Billing Complexity in Texas: Generic RCM vs. MBC<\/h3>\n\n\n\n\n\n\n\n\n\n\n\n\n
Revenue Challenge<\/strong><\/th>\nGeneric RCM<\/strong><\/th>\nMBC Texas Neurology<\/strong><\/th>\n<\/tr>\n<\/thead>\n
Novitas LCD Compliance<\/td>\nReactive post-denial appeals<\/td>\nPre-submission Novitas-specific documentation protocols<\/td>\n<\/tr>\n
TX Medicaid STAR\/STAR+PLUS<\/td>\nStandard submission<\/td>\nSTAR MCO-specific neurology billing + contract analytics<\/td>\n<\/tr>\n
Infusion Therapy (MS Biologics)<\/td>\nBasic J-code submission<\/td>\nReal-time HCPCS integration + dosing unit verification<\/td>\n<\/tr>\n
MA Diagnostic Interpretation Review<\/td>\nManual appeals<\/td>\nNLP-resistant documentation + algorithmic denial defense<\/td>\n<\/tr>\n
E\/M MDM Documentation<\/td>\nPeriodic audits<\/td>\nProvider-specific MDM coaching + pre-submission review<\/td>\n<\/tr>\n
Net Collection Ratio<\/td>\n85%\u201391%<\/td>\n93%\u201397%<\/td>\n<\/tr>\n
Denial Rate<\/td>\n11%\u201315%<\/td>\n3%\u20135%<\/td>\n<\/tr>\n
Days in AR<\/td>\n42\u201358 days<\/td>\n18\u201324 days<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
\n

MBC Spotlight: Texas Neurology Revenue Integrity in Practice<\/h3>\n

MBC’s neurology billing services in Texas<\/a><\/strong> operate through a denial root-cause engineering model \u2014 not a claims clearinghouse. Every Texas neurology engagement begins with a Complimentary 90-Day AR Diagnostic that maps your current denial distribution by payer, procedure category, and provider, quantifies your recoverable leakage against specialty benchmarks, and builds a payer variance detection protocol calibrated to your Novitas MAC jurisdiction and Texas commercial payer mix.<\/p>\n

What the 90-Day AR Diagnostic delivers for Texas neurology groups:<\/p>\n